|Specificity:||The antibody MEM-78 reacts with CD10 antigen (CALLA - Common acute lymphatic leukemia antigen), a 100 kDa type II integral membrane protein.
HLDA IV; WS Code B 506
HLDA V; WS Code B CD10.4
|Immunogen:||NALM-6 human pre-B cell line|
|Preparation:||The purified antibody is conjugated with Fluorescein isothiocyanate (FITC) under optimum conditions. The reagent is free of unconjugated FITC and adjusted for direct use. No reconstitution is necessary.|
|Storage Buffer:||The reagent is provided in stabilizing phosphate buffered saline (PBS) solution containing 15mM sodium azide.|
|Storage / Stability:||Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not use after expiration date stamped on vial label.|
|Usage:||The reagent is designed for Flow Cytometry analysis of human blood cells using 20 μl reagent / 100 μl of whole blood or 106 cells in a suspension.
The content of a vial (2 ml) is sufficient for 100 tests.
|Expiration:||See vial label|
|Lot Number:||See vial label|
|Background:||CD10 (neutral endopeptidase – NEP, common acute lymphocytic leukemia antigen – CALLA, membrane metallo-endopeptidase – MME, enkefalinase) is a 100-kDa cell surface zinc metalloprotease cleaving peptide bonds on the N-terminus of hydrophobic amino acids and inactivating multiple physiologically active peptids. CD10 is expressed on various normal cell types, including lymphoid precursor cells, germinal center B lymhocytes, and some epithelial cells, and its expression level serves as a marker for diagnostics of many carcinomas. CD10 is also a differentiation antigen for early B-lymphoid progenitors in the B-cell differentiation pathway and has a key role in regulation of growth, differentiation and signal transduction of many cellular systems.|
*Suzuki T, Ino K, Kikkawa F, Uehara C, Kajiyama H, Shibata K, Mizutani S: Neutral endopeptidase/CD10 expression during phorbol ester-induced differentiation of choriocarcinoma cells through the protein kinase C- and extracellular signal-regulated kinase-dependent signalling pathway. Placenta. 2002 Jul;23(6):475-82.
*Yada K, Kashima K, Daa T, Kitano S, Fujiwara S, Yokoyama S: Expression of CD10 in basal cell carcinoma. Am J Dermatopathol. 2004 Dec;26(6):463-71.
*Braham H, Trimeche M, Ziadi S, Mestiri S, Mokni M, Amara K, Hachana M, Sriha B, Korbi S: CD10 expression by fusiform stromal cells in nasopharyngeal carcinoma correlates with tumor progression. Virchows Arch. 2006 Aug;449(2):220-4.
*Dall'Era MA, True LD, Siegel AF, Porter MP, Sherertz TM, Liu AY: Differential expression of CD10 in prostate cancer and its clinical implication. BMC Urol. 2007 Mar 2;7:3.
*Horejsi V, Angelisova P, Bazil V, Kristofova H, Stoyanov S, Stefanova I, Hausner P, Vosecky M, Hilgert I: Monoclonal antibodies against human leucocyte antigens. II. Antibodies against CD45 (T200), CD3 (T3), CD43, CD10 (CALLA), transferrin receptor (T9), a novel broadly expressed 18-kDa antigen (MEM-43) and a novel antigen of restricted expression (MEM-74). Folia Biol (Praha). 1988;34(1):23-34.
*Leukocyte Typing IV., Knapp W. et al. (Eds.), Oxford University Press (1989).
*Leukocyte Typing V., Schlossman S. et al. (Eds.), Oxford University Press (1995).
*Angelisová P, Drbal K, Horejsí V, Cerný J: Association of CD10/neutral endopeptidase 24.11 with membrane microdomains rich in glycosylphosphatidylinositol-anchored proteins and Lyn kinase. Blood. 1999 Feb 15;93(4):1437-9.
For laboratory research only, not for drug, diagnostic or other use.
EXBIO Praha | Nad Safinou II 341 | 252 50 Vestec u Prahy | Czech Republic